Founded in 2005, Lewei Pharma is a contract development and manufacturing organization (CDMO) focused on chemical process development and industrialization for innovative drugs. Its services cover process research, development, optimization, pilot and industrial production from preclinical stages through commercialization. The company has deployed R&D centers, production bases and an overseas business center and works with numerous global innovative-drug clients. Lewei handles hundreds of R&D and production project orders annually across therapeutic areas including oncology, central nervous system and metabolic diseases. Management highlights an experienced international service team and a competitive position in the small-molecule CDMO field. The company plans to use new funding to build a Cangzhou CDMO base, a Hefei new-drug R&D and GMP production base, and a Shanghai innovation accelerator laboratory.

Total raised

$78M

Funding rounds

1

Latest round

Series C

Latest activity

Oct 2021